2023-07-18 19:58:50
New Alzheimer’s Drug Shows Promise in Slowing Disease Progression
Frankfurt – A new Alzheimer’s drug developed by US pharmaceutical company Eli Lilly has shown significant potential in slowing down the progression of the disease, according to study results. The drug, called donanemab, has demonstrated a 35 percent reduction in cognitive impairment compared to a placebo.
The study, conducted in collaboration with several universities, involved over 1700 participants. Those who received the monthly infusion of donanemab over 18 months showed a notable decrease in cognitive decline. Experts have hailed these findings as great progress in Alzheimer’s research, although they also caution against potential side effects.
Early diagnosis is believed to be crucial for the most effective treatment of Alzheimer’s. Research has shown that early signs can appear up to nine years before an official diagnosis. The disease is characterized by the presence of two forms of protein deposits in the brain. Donanemab works to combat the beta-amyloid deposits, reducing plaque by an average of 84 percent after 18 months of treatment.
The potential slowdown of cognitive decline by 35 percent means that individuals with Alzheimer’s can continue to perform everyday tasks such as shopping, managing finances, and household chores. This breakthrough could greatly improve the quality of life for the estimated 30 million people worldwide who suffer from Alzheimer’s.
The British research institute Alzheimer’s Research has also conducted its own study on donanemab and expressed optimism about its potential. They believe that this drug could herald a new era in which Alzheimer’s becomes a treatable condition. The Alzheimer’s Society charity has echoed this sentiment, stating that drugs like donanemab could be the beginning of the end for Alzheimer’s disease, comparing it to long-term conditions like asthma or diabetes.
However, the study also revealed some serious side effects associated with donanemab, including brain swelling. Three deaths were classified as “treatment-related” in the donanemab group, and one death was recorded in the placebo group. Further research is necessary to minimize these treatment risks.
Overall, the results of the study represent a significant advancement in the fight against Alzheimer’s. Doctor Richard Oakley, Associate Research Director of the Alzheimer’s Society, described it as a game changer and emphasized that slowing down the disease is indeed possible. Drugs like donanemab could pave the way for a future where Alzheimer’s disease is viewed as a manageable long-term condition.
It is important to note that this article provides general information about the Alzheimer’s drug and should not be used for self-diagnosis, treatment, or medication. Individuals are advised to consult a doctor for personalized medical advice.]
#drug #slows #disease